Acquisitions - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Feb. 28, 2019	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Business Acquisition [Line Items]
Goodwill		$ 140,627,000	$ 140,627,000
Change in the estimated fair value of contingent consideration		14,750,000	(638,000)	$ (40,773,000)
Cobalt Biomedicine, Inc | Acquisition Agreement
Business Acquisition [Line Items]
Business acquisition, percentage of voting interests acquired	100.00%
Business acquisition, impairment of intangible assets or goodwill	$ 0
Goodwill	140,600,000	140,600,000
Maximum contingent consideration upon achievement of certain pre-specified development milestones	$ 500,000,000
Maximum term for success payment	20 years
Estimated fair value of contingent consideration		123,700,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Research and Development Expense
Business Acquisition [Line Items]
Change in estimated fair value of success payment		13,600,000	6,900,000	7,900,000
Change in the estimated fair value of contingent consideration		14,700,000	600,000	$ 40,800,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Short-term Liabilities
Business Acquisition [Line Items]
Estimated fair value of contingent consideration		40,200,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Long-term Liabilities
Business Acquisition [Line Items]
Estimated fair value of success payment liability		17,900,000	4,200,000
Estimated fair value of contingent consideration		$ 83,500,000	$ 109,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Minimum
Business Acquisition [Line Items]
Threshold market capitalization	$ 8,100,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | Market Capitalization Equal to or Exceeds $8.1 billion
Business Acquisition [Line Items]
Cobalt success payment	500,000,000
Cobalt Biomedicine, Inc | Acquisition Agreement | IPR&D
Business Acquisition [Line Items]
Business combination, intangible assets	$ 59,200,000